This page is used for Login Customizer plugin. It will not be visible to your readers. Do not delete it.
- AACR 2022: Tollys releases new preclinical data demonstrating lifelong potent anti-tumor immunity of TL-532
- Tollys and Gustave Roussy enter into new research agreement
- Synthetic TLR-3 ligands
- Discovery process and in vitrobiological characterization of rationally designed TL-532 Toll-like Receptor 3 (TLR3) agonist as anti-cancer molecule
- First Rationally Designed TLR3 Agonist “TL-532”Induces Tumor Specific Apoptosis, Microenvironment Switch and Immune Stimulation, Leading to Life-long Anti-tumor Auto-vaccination